Spruce Street Capital LP Makes New $1.74 Million Investment in Lexeo Therapeutics, Inc. $LXEO

Spruce Street Capital LP bought a new position in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 175,000 shares of the company’s stock, valued at approximately $1,738,000. Lexeo Therapeutics comprises about 0.6% of Spruce Street Capital LP’s portfolio, making the stock its 25th biggest holding. Spruce Street Capital LP owned about 0.24% of Lexeo Therapeutics as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Lexeo Therapeutics by 69.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock worth $35,000 after acquiring an additional 1,459 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Lexeo Therapeutics by 6.1% during the 3rd quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock worth $188,000 after acquiring an additional 1,626 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of Lexeo Therapeutics by 19.5% during the 4th quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock worth $141,000 after acquiring an additional 2,317 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Lexeo Therapeutics by 25.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,893 shares of the company’s stock worth $118,000 after acquiring an additional 2,427 shares during the last quarter. Finally, AXQ Capital LP grew its holdings in Lexeo Therapeutics by 19.6% in the 3rd quarter. AXQ Capital LP now owns 14,921 shares of the company’s stock valued at $99,000 after buying an additional 2,446 shares in the last quarter. 60.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on LXEO shares. Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday. Chardan Capital reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a report on Monday, May 11th. Finally, Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Lexeo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.14.

Lexeo Therapeutics Stock Up 6.4%

LXEO stock opened at $4.65 on Tuesday. Lexeo Therapeutics, Inc. has a 12 month low of $3.60 and a 12 month high of $10.99. The firm has a market cap of $365.12 million, a P/E ratio of -3.21 and a beta of 1.39. The company’s 50-day moving average price is $5.50 and its two-hundred day moving average price is $7.01.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Equities analysts predict that Lexeo Therapeutics, Inc. will post -1.23 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the sale, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at $1,935,203.14. This trade represents a 13.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 59,644 shares of company stock valued at $336,462 over the last quarter. Company insiders own 2.00% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.